Recall
FDAHealthFebruary 12, 2026

Slate Run Pharmaceuticals — Eptifibatide Injection, 75 mg/100 mL vial for weight-adjusted bolus dosing, 1x100 mL Single-dose Vial, For Intravenous Use Only, Rx Only, Manufactured by: Hainan Poly Pharm

⚠️ Labeling: Not Elsewhere Classified. The carton for Eptifibatide Injection 75 mg/100 mL states 75 mg/100 mL vial for weight-adjusted bolus dosing. The approved statement is 75 mg/100 mL vial for weight-adjusted infusion.

Is this relevant to me?

Geography
Nationwide
Source agency
FDA
Category
Health
Published
February 12, 2026

Nationwide within the USA.

What's affected?

Product
Eptifibatide Injection, 75 mg/100 mL vial for weight-adjusted bolus dosing, 1x100 mL Single-dose Vial, For Intravenous Use Only, Rx Only, Manufactured by: Hainan Poly Pharm. Co., Ltd., Guilinyang Economic Development Area, Haikou, Hainan Province, China 571127; Distributed by: Slate Run Pharmaceuticals, LLC, Columbus, Ohio 43215. NDC Slate Run Carton Label: 70436-027-80; NDC ProRx Carton Label: 70436-163-80
UPC
0370436027804
Lot code
within

Additional details

All lots within expiry

What should I do?

Recommended action

Class III recall. Voluntary: Firm initiated Quantity affected: N/A.

View original FDA notice →

Get Health recall alerts

Delivered to your inbox. Free. No account required.